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Summary: A method for the determination of glucose is described. H202, produced by the action of glucose oxidase,
is measured from the change in absorbance due to oxidation of NAD(P)H in the presence of catalase, aldehyde de-
hydrogenase and a high concentration of ethanol. The quality data of the method are equivalent to those of the
hexokinase-glucose-6-phosphate dehydrogenase method used as reference.
Eine neue enzymatische Methode zur Bestimmung von Glucose
Zusammenfassung: Bei der beschriebenen Glucosebestimmung wird das durch Glucoseoxidase entstandene H202 mit
Katalase und Aldehyddehydrogenase in Anwesenheit von hohen Ethanolkonzentrationen bestimmt; dabei dient
NAD(P)H als Meßgröße. Die Qualitätsmerkmale der Methode entsprechen denen der Hexokinase-Glucose-6-phos-
phatdehydrogenase Referenzmethode.
Introduction
Glucose determination is one of the most frequently
used methods in clinical chemistry, and is based mainly
on three enzymatic-photometric assays: the NADP
dependent hexokinase-glucose-6-phosphäte dehydro-
genase method (1), the NAD-dependent glucose dehy-
drogenase method (2) and the H202 -producing glucose
oxidase-peroxidase method coupled with leuco dyes (3).
Our assay is based on the glucose oxidase reaction, with
measurement of the produced H2O2 , using catalase and
NAD(P)-dependent aldehyde dehydrogenase in the
presence of high ethanol concentrations. This principle
(4), which has already been evaluated for uric acid (5)
and cholesterol (6) avoids the known difficulties arising
from the use of peroxidäse coupled with leuco dyes.
Reactions
(1) P-glueose
(2) H202 + ethanol
(3)
aldehyde
dehydrogenase
2H2O
acetic acid + NAD(P)H
*) This work contains part of the doctor thesis of 7%. W, Beu*
hausen
Materials and Methods
KCl-diphosphate buffer (pH 8.0): Dissolve 11.15 g tetrasodium-
diphosphate-10-hydrate (Merck No. 6591) and 11.85 g KC1
(Merck No. 4936) in 400 ml H2O; adjust pH to 8.0 with HC1
and add H2O to 500 ml.
Aldehyde dehydrogenase solution: Dissolve a 10 U equivalent of
aldehyde dehydrogenase, K* activated from baker's yeast,
grade II (No. A-6758, Fa. Sigma, St. Louis) in 1 ml H2O.
NAD-solution: Dissolve 10 mg NAD (No. 15298, Fa. Boehringer,
Mannheim) in 1 ml H2O.
Glucose oxidase solution: Dissolve an 1100 U equivalent of
glucose oxidase lyophilisate (No. 15426, Fa. Boehringer, Mann-
heim) in 0.5 ml H2O.
Buffer/ethanol mixture: Mix 10 ml buffer and 1 ml ethanol.
Catalase: Catalase 1.43 GU/1 (Fa. CalBiochem., Lot. 600660).
Reaction mixture (for 10 determinations): Take 8.5 ml buffer/
ethanol mixture, add 1 ml NAD-solution, 1 ml aldehyde dehy-
drogenase solution, 0.5 ml glucose oxidase solution, and 10
catalase.
This mixture is incubated at room temperature for 1 h. At 4 °C,
it is stable for approximately 24 h.
Manual procedure
Pipette 1 ml of the reaction mixture into a semimicro cuvette
with 10 mm optical path length, then read absorbance for
1-3 min at 334 or 340 nm Hg and add 5 sample. Mix, then
read absorbance when the reaction has come to the end (reac-
tion temperature: 25 °C). Before and after the'end of the reac-
tion a slight endogenous slope is found. By extrapolation back
to the starting point the absorbance difference is determined.
The glucose concentration is calculated from the absorbance
difference. By using NADP instead of NAD identical results were
obtained.
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Results
The accuracy of the method was established by deter-
mining the glucose concentration in aqueous solutions
of known glucose concentrations, in control sera con-
taining known concentrations and by determination of
the glucose concentration in patients' sera with our
method and the hexokinase-glucose-6-phosphate dehy-
drogenase method (1). The results of both methods
were compared with the paired-t-test, which did not
show significant differences. The regression analysis for
patients' sera is shown in figure 1.
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Fig. 1. Linear regression for glucose concentration in 29 patients'
sera determined with the glucose oxidase-aldehyde de-
hydrogenase method (y) and the hexokinase-glucose-6-
phosphate dehydrogenase method (x).
y = 1.00-0.03 r = 0.999 ç = 58
Paired t-test:
f = 5 7 á = 0.05 t0 =1.43
The precision from day to day for control sera was
CV < 3.08% (n = 55), which almost meets the figure of
the American College of Pathologist* (CV < 2.2%) (7),
and which is well below the requirements of the guide-
lines of the Medical Society of the Federal Republic
of Germany (CV < 5%) (7).
For normal sera or those with slight haemolysis, hyper-
lipidaemia or hyperbilirubinaemia, the absorbance value
of the sample is negligible. For strongly haemolytic
samples, turbid hyperlipidaemic samples or samples
with well elevated bilirubin levels (> 115 ìðéïÀ/ß), the
absorbance value of the sample volume has to be deter-
mined in a reaction mixture without glucose oxidase,
and then subtracted.
Discussion
The described method is suitable for the determination
of glucose in human sera. The linear range of the method
was verified for concentrations from 2-38 mmol/1, thus
permitting determination of almost any normal or
pathologic glucose concentration.
Relevant inhibitor substances for glucose oxidase or
aldehyde dehydrogenase are not known in human sera.
For the evaluation of a uric acid determination method,
which has the same indicator system, a number of sub-
stances often used clinically were tested for possible
interference. No interference by these substances was
noted (5).
Compared to other glucose oxidase methods coupled
with leuco dyes, our method has several advantages: The
reaction time is 10-15 min shorter. The glucose con-
centration can be calculated directly from the absorb-
ance difference using the coefficient of absorbance for
NAD(P)H. Stabilisation of the indicator is not necessary.
The manual procedure for our method is rather simple
and it can be easily automatized.
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Summary: The present study shows an increased urinary cyclic guanosine S'.S'-monophosphate (cyclic GMP) excre-
tion rate in children of all age groups bearing malignant tumours or lymphomas. The incidence of increased cyclic
GMP excretion was highly significant (79%). Follow-up studies of up to three years have revealed that during periods
of remission of malignant disease the urinary cyclic GMP excretion drops to near normal values, whereas recurrences
are accompanied by a new increase of cyclic GMP excretion.
Ausscheidung von zyklischem Guanosin-3'.5'-monophosphat im Urin von Kindern mit malignen Tumoren
Zusammenfassung: Die vorliegende Studie zeigt eine erh hte Ausscheidung von zyklischem Guanosin-S'.S'-mono-
phosphat (zyklisches GMP) im Urin von Kindern aller Altersgruppen mit malignen Tumoren oder Lymphomen. Das
Auftreten dieser zyklischen GMP-A sscheidung im Urin war mit 79% hoch signifikant. Verlaufsstudien bis zu 3 Jah-
ren zeigten w hrend der Remission der malignen Erkrankung eine Ausscheidung, die bis zu Normalwerten abfiel, hin-
gegen waren Rezidive von einer erneuten Erh hung der Ausscheidung von zyklischem GMP begleitet.
Introduction Material and Methods
Earlier Observations (1,2) have suggested that an eleva- Urine was collected at room temperature and was stored at
tion Of guanosine 3'.5'-monophpSphate (cyclic GMP) - 20 °C until assayed. The urinary cyclic GMP was measured by
^ j n j . . . ** j ÷ é /^\ j · ÷ ' ÷ - j a radioisotope dilution test with cyclic GMP binding protein
promoted cell division. Murad et al. (3) demonstrated
 (Boehringer, Mannheim, Germany) (5-7). Urinary levels of
an increased urinary excretion of cyclic GMP in rats creatinine were determinated by the picric acid method (8). The
bearing tfansplantable liver and kidney tumours. The values reP°rted for urinary <*°1ßï GMP e*<*eti°n «the mean
. ^ ,. ' ^ \.« . V · é j " Ë values of duplicate de terminations and are expressed as ìðéïß
excretion of cyclic GMP in these animals decreased
 per g creatinine.
after radiotherapy, chemotherapy, or excision of the
tumours and correlated well with the tumour size
and growth. The same group (4) found that urinary Results and Discussion
cyclic GMP, but not cyclic denosine 3'.5'-monophos- Several reported data demonstrate a positive correlation
phate (cyclic AMP), increased progressively with the between the intracellular level of cyclic GMP and the
growth of several, but not all transplantable liver and
 ceu proliferation (1, 2). Therefore, it seemed possible
kidney tumours studied. Stimulated by these findings that newborn children would have an elevated excretion
we made an attempt to correlate the urinary cyclic
 of cyclic GMP due to their higher rate of cell prolifera-
GMP excretion rate (/imol per gram ereatinine) with the tion. Figure 1 shows the urinary excretion of cyclic
clinical course of malignant tumours in children. GMP by children as a function of age. The youngest
children were premature births (36 weeks of pregnancy).
:—~--~· The excretion rates of cyclic GMP were considerably
*) Parts of this paper were presented as a preliminary communi- higher in young children (below 2 years) and decreased
with
 ·». ™- -ult is probably due to the normally
1979, Salzburg, Austria. decreased excretion of creatmine in young children (9,
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Fig. 1. Urinary cyclic GMP excretion rates in children, as a func-
tion of age.
10), rather than by an increased level of cyclic GMP.
The upper limit of urinary excretion of cyclic GMP in
children younger than two years, is 5 ìðéïÀ/g creatinine;
whereas the normal range in children older than 2 years
Tab. 1. Urinary cyclic GMP excretion rates in children with
tumours and other diseases (Pediatric Clinic of the Uni-
versity of Innsbruck/Austria; observation period: 197Ô-
É 979).
Cyclic GMP
(ìðéïÀ/g
creatinine)
Untreated
tumours*)
Untreated
leukaemias**)
Recurrences of
leukaemias
total:
Treated
tumours
Leukaemias in
remission
Other
diseases
<1.0
4
1
2
7
19
13
33
1.0-
1.50
8
1
2
11
22
18
32
1.51-
2.0
16
4
7
27
2
11
9
>2.0
25
11
6
42
8
6
11
Values
77
88
76
79
21
35
24
*) Total 53 determinations; number of cases in brackets: brain
tumours (13) (ependymoma (2), craniopharyngioma (2),
pineal tumour (1), medulloblastoma (3), spongioblastom
(1), brainstem tumour (1), astrocytoma (2), unclassified
(2)); lymphomas (7) (M.Hodgkin: stage I (1), stage III (1),
AurfaYMymphoma (1), non-/fod£fci>i-lymphoma stage IV (4));
Wilms tumours (5) (stage II (3), stage III (1), stage. IV (1));
neuroblastomas stage IV (3) sarcomas (3) (stage IV (1),
sarcoma botryoides (1), angiosarcoma (1)); osteosarcomas
without metastases (2).
2 determinations were performed at different time points in
5 cases (brain tumour, Wilms tumour, neuroblastoma,
sarcoma and lymphoma), and 15 values are determinations
during the recurrences of the tumours (brain tumours, Wilms
tumours, neuroblastoma, sarcoma and lymphomas).
**) acute lymphatic leukaemias (12), acute myeloic leukaemias
(2), and acute monocytic leukaemia (1). 2 determinations
were performed at different time points in 2 cases (acute
lymphatic leukaemia).
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Fig. 2. Urinary cyclic GMP excretion rates in children bearing
malignant tumours and lymphoproliferative diseases, as a
function of age.
ð untreated tumours, ï treated tumours
Ä
 brain tumours.
is 0.5-1.2 ìðéïÀ/g creatinine. The normal level of cyclic
GMP in plasma has been determined as 1.2 nmol/1; this
level is extremely constant.
As shown in figure 2, elevated excretion rates of cyclic
GMP were found in children with treated and untreated
malignant tumours. The excretion rates of some untreated
tumour patients were ten times the normal level as
shown in figure 1. The mean increase in cyclic GMP
excretion was lower in patients who were already under
radio- or chemotherapy when the first analysis was made
(fig. 2). Brain tumours, with 2 exceptions, yielded little
or no elevation of the cyclic GMP excretion rate.
Table 1 shows 186 determinations of the excretion rates
of cyclic GMP in 70 children older than 2 years bearing
malignant tumours or lymphoproliferative diseases. The
highest percentage of elevated rates was found in patients
with untreated malignant tumours (69 of 87), while in
patients with malignant tumours undergoing treatment
as well as with malignant tumours in remission the ratio
was considerably lower (10 of 51 and 17 of 48, respecti-
vely). In a control group of 85 patients with other non-
proliferative diseases, 20 also had elevated excretion
rates.
Follow-up studies up to 3 years revealed that urinary
cyclic GMP excretion drops to near normal values in
patients during remission of their disease, while recur-
rences are accompanied or preceded by a rise of cyclic
GMP excretion. In cases of Wilms tumour (fig. 3)
nephrectomy was followed by a drastic drop of cyclic
GMP excretion. Another patient (fig. 4) with acute
myelosis gave a similar response after chemotherapy. A
recurrence of the disease was accompanied by a second
increase of cyclic GMP excretion.
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 9
Puschendorf, Grunicke, Jentsch and Berger: Urinary cGMP in children with malignant tumours 981
12
1977 1978
Time [month,year]
4 6 8 10 12*
1979 I
Fig. 3. Follow-up study of urinary cyclic GMP excretion rates:
Wilms tumour (stage II) (M.R.) 8. 11.1977 nephrectomy
right, subsequent radiotherapy (18 Gy (1800 rad)) and
usual chemotherapy (actinomycin & vincristine) (11) for
2 years.
Our results for children with malignant tumours should
not be generalized to include adults. Adult tumour
patients (total 61) also show an increase in 61% of
treated and untreated malignant tumours, but an increase
is also found in 38% of other diseases — especially in
cases of myocardial insufficiency (Puschendorf, /?.,
Michelmayr, G. &Dienstl, F., unpublished results). Only
26% of patients (total 152) with untreated gynaecologi-
cal tumours showed an increased cyclic GMP excretion
in the urine (PuschendorfLB.9 Santeler,P. &Dapunt, Ï.,
unpublished results).
Together with other clinical parameters the determina-
tion of urinary excretion of cyclic GMP seems to be use-
ful for tumour diagnosis and the assessment of therapeu-
tic response in children. So far, the excretion rate of
cyclic GMP cannot be correlated with the size or clinical
stage of localized tumours, since the number of cases of
each type of tumour was too low. However, in 12 patients
1st Recurrence
27.4.
j é L
8 9 10 11 12
1977
J—I—I—I
4 6 8 10 Ô1978 ;
Time (month.year]
J—é—\ é é
12 2 4 6 8 10 12
I 1979
2 4 6
1980
Fig. 4. Follow-up study of urinary cyclic GMP excretion rates:
acute lymphatic leukaemia (L.K.), therapy: 0-76 scheme
(vincristine, daunoblastine & dexamethasone) modified
according to Pinkel (12).
with acute lymphatic leukaemia we found that there is
no correlation between cyclic GMP and haematological
findings.
The determination of cyclic GMP in the urine is of no
use for the diagnosis of gynaecological tumours. For
other malignant tumours in adults, the measurement of
cyclic GMP in urine has approximatively the same value
as other in vitro tests available. None of the established
in vitro tests gives positive results for all tumour cases.
The confidence level of tumour diagnosis by in vitro
tests increases with the number of independent tests. In
this sense, the determination of cyclic GMP excretion in
urine complements the list of in vitro tumour tests.
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